% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Liu:267555,
      author       = {Y. Liu and A. Keib and B. Neuber and L. Wang and A.
                      Riemer$^*$ and M. Bonsack$^*$ and A. Hückelhoven-Krauss and
                      A. Schmitt and C. Müller-Tidow and M. Schmitt},
      title        = {{D}efinition and {C}haracterization of {SOX}11-{D}erived
                      {T} {C}ell {E}pitopes towards {I}mmunotherapy of {G}lioma.},
      journal      = {International journal of molecular sciences},
      volume       = {24},
      number       = {3},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2023-00333},
      pages        = {1943},
      year         = {2023},
      abstract     = {The transcription factor SOX11 is a tumor-associated
                      antigen with low expression in normal cells, but
                      overexpression in glioblastoma (GBM). So far, conventional
                      surgery, chemotherapy, and radiotherapy have not
                      substantially improved the dismal prognosis of
                      relapsed/refractory GBM patients. Immunotherapy is
                      considered a promising strategy against GBM, but there is a
                      fervent need for better immunotargets in GBM. To this end,
                      we performed an in silico prediction study on SOX11, which
                      primarily yielded ten promising HLA-A*0201-restricted
                      peptides derived from SOX11. We defined a novel peptide
                      FMACSPVAL, which had the highest score according to in
                      silico prediction (6.02 nM by NetMHC-4.0) and showed an
                      exquisite binding affinity to the HLA-A*0201 molecule in the
                      peptide-binding assays. In the IFN-γ ELISPOT assays,
                      FMACSPVAL demonstrated a high efficiency for generating
                      SOX11-specific CD8+ T cells. Nine out of thirty-two healthy
                      donors showed a positive response to SOX11, as assessed by
                      the ELISPOT assays. Therefore, this novel antigen peptide
                      epitope seems to be promising as a target for T cell-based
                      immunotherapy in GBM. The adoptive transfer of in vitro
                      elicited SOX11-specific CD8+ T cells constitutes a potential
                      approach for the treatment of GBM patients.},
      keywords     = {HLA-A*0201 (Other) / SOX11 (Other) / glioma (Other) /
                      immunotherapy (Other) / tumor-associated antigen (Other)},
      cin          = {F130},
      ddc          = {540},
      cid          = {I:(DE-He78)F130-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36768267},
      doi          = {10.3390/ijms24031943},
      url          = {https://inrepo02.dkfz.de/record/267555},
}